ASCOR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ascor, and when can generic versions of Ascor launch?
Ascor is a drug marketed by Mcguff, Fresenius Kabi Usa, and Stira. and is included in three NDAs.
The generic ingredient in ASCOR is ascorbic acid. Three suppliers are listed for this compound. Additional details are available on the ascorbic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ascor
A generic version of ASCOR was approved as ascorbic acid by FRESENIUS KABI USA on August 7th, 2025.
US Patents and Regulatory Information for ASCOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mcguff | ASCOR | ascorbic acid | SOLUTION;INTRAVENOUS | 209112-001 | Oct 2, 2017 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Fresenius Kabi Usa | ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 217131-001 | Aug 7, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Stira | ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 220172-001 | Jul 30, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
